A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55–75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam)
- 30 December 2005
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 66 (6) , 604-612
- https://doi.org/10.1002/pros.20352
Abstract
BACKGROUND The identification of predictors for prostate biopsy outcome at two screening rounds using a PSA ≥3.0 ng/ml as biopsy indication. MATERIALS AND METHODS We compared predictors by means of descriptive statistics and logistic regression analysis in men (55–75 years) biopsied in either the 1st or 2nd screening round of ERSPC Rotterdam (interval 4 years). RESULTS Positive predictors for biopsy outcome in both screening rounds were an increased PSA level in the absence of a previous negative biopsy (PrevNB), DRE and TRUS suspicious and a positive family history (PFH). A higher than median prostate volume was a consistent negative predictor. Having had a PrevNB at initial screening strongly reduced the chance of cancer detection at repeat screening and in addition canceled the predictive potential of PSA. CONCLUSION If “detecting prostate cancer efficiently” were the aim, this study indicates that a “PSA only based biopsy threshold” may be replaced by another criterion incorporating, e.g., DRE, TRUS and prostate volume in men who were biopsied in the preceding 4 year interval. Prostate 66:604–612, 2006.Keywords
This publication has 9 references indexed in Scilit:
- Incidence and follow‐up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 yearsCancer, 2005
- Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands)BJU International, 2003
- Interval carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Rotterdam.JNCI Journal of the National Cancer Institute, 2003
- Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels ≤ 10 ng/mLCancer, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/mlUrology, 2002
- Parameterization of Multivariate Random Effects Models for Categorical DataBiometrics, 2001
- Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate DiseaseJAMA, 1992